Bob Oliver Sells 18,647 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Bob Oliver sold 18,647 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the sale, the director now owns 33,514 shares of the company’s stock, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Exelixis Price Performance

Shares of EXEL stock opened at $37.65 on Friday. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $38.43. The stock’s 50-day moving average is $34.42 and its two-hundred day moving average is $31.54. The firm has a market cap of $10.54 billion, a P/E ratio of 21.27, a PEG ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EXEL. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Brookline Capital Management began coverage on Exelixis in a research note on Monday, December 23rd. They set a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating and set a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Finally, Piper Sandler boosted their price objective on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.24.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Coppell Advisory Solutions LLC bought a new stake in shares of Exelixis during the 4th quarter worth about $25,000. Colonial Trust Co SC boosted its stake in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 765 shares in the last quarter. USA Financial Formulas bought a new stake in shares of Exelixis during the 4th quarter worth about $32,000. Principal Securities Inc. boosted its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Finally, Kestra Investment Management LLC bought a new stake in shares of Exelixis during the 4th quarter worth about $39,000. 85.27% of the stock is owned by institutional investors and hedge funds.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.